Log in to your Inderes Free account to see all free content on this page.
Amniotics
0.006 SEK -1.75%2 investors are following this company
Amniotics develops and manufactures stem cell therapies in our own GMP certified facility. Amniotics was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Center and Hospital, the company is pioneering the harvesting and propagation of tissue-specific neonatal quality mesenchymal stem cells (MSC). The company is listed at Nasdaq First North Growth Market in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
AMNI
Daily low / high price
0.006 / 0.006
SEK
Market cap
15.31M SEK
Turnover
24.87K SEK
Volume
4.3M
Latest videos
Financial calendar
Interim report
20.08.2024
Annual report
18.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
LSCS Invest AB | 10.6 % | 10.6 % |
Deflexum AB | 10.3 % | 10.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Statement from the Board of Directors of Amniotics regarding the merger with Magle Group
Magle Group and Amniotics merge to create a leader in high-quality life-changing healthcare innovations with a broadened CDMO offering
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio